From the failures of CETP inhibition to a new hope in the fight against cardiovascular risk
The Molecular Paradox of CETP Inhibition: To understand the renewed interest in this molecule, it is worth taking a closer look at the complex architecture of lipid transport. Cholesteryl ester transfer protein (CETP) plays a central role in the exchange of lipids among circulating lipoproteins. It transfers cholesteryl esters from HDL particles to apolipoprotein B–containing lipoproteins, principally LDL and VLDL, in exchange for triglycerides.
Inhibiting CETP profoundly alters this lipid traffic. By preventing the transfer of cholesteryl esters from HDL to atherogenic lipoproteins, HDL cholesterol levels rise, while LDL cholesterol and other atherogenic lipoproteins decline.
Yet this mechanism should not be interpreted too simply. An increase in HDL cholesterol does not necessarily translate into greater cardiovascular protection, as earlier CETP inhibitors clearly demonstrated. What matters is the overall effect on lipoprotein metabolism and, above all, whether lowering LDL cholesterol and other atherogenic lipoproteins ultimately translates into fewer cardiovascular events.
Obicetrapib stands out because of the magnitude and consistency of its effects on the lipid profile. In the phase 3 BROADWAY trial, conducted in patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia who were receiving maximally tolerated lipid-lowering therapy, obicetrapib reduced LDL cholesterol by approximately 30% from baseline and by an additional 33% compared with placebo at 12 weeks. It also produced substantial increases in HDL cholesterol and reductions in other atherogenic lipoproteins.
The mechanism underlying the reduction in LDL cholesterol is complex and should not be reduced to the notion that these particles are left “deprived” of lipids. CETP inhibition alters the lipid composition and metabolism of apolipoprotein B–containing lipoproteins, ultimately promoting their clearance.
The clinically relevant consequence is reduced circulating exposure to atherogenic particles, particularly LDL. This is one of the reasons obicetrapib has attracted considerable interest. It affects several components of the atherogenic burden, including LDL cholesterol and apolipoprotein B, and has also shown effects on lipoprotein(a).
The Adherence Challenge and the Appeal of Oral Therapy: Contemporary cardiovascular medicine continues to confront the problem of residual cardiovascular risk, the risk that persists despite substantial LDL cholesterol reduction with available therapies.
When statins, ezetimibe and other strategies fail to bring patients to their therapeutic targets, treatments directed against PCSK9 provide highly effective alternatives. These include alirocumab and evolocumab, monoclonal antibodies administered subcutaneously, and inclisiran, a small interfering RNA that reduces hepatic production of PCSK9. These approaches can produce substantial reductions in LDL cholesterol and have significantly expanded the therapeutic arsenal against hypercholesterolemia.
Obicetrapib introduces an important practical difference. It is a small molecule administered orally once daily, eliminating the need for injections and simplifying long-term treatment. This may facilitate its incorporation into everyday life, although adherence remains a challenge with any chronic oral medication and should never be taken for granted.
It would also be premature to claim that obicetrapib will necessarily be less expensive than biological therapies. Its eventual cost will depend on multiple factors, including commercial strategy, reimbursement policies and healthcare systems in individual markets. Any economic advantage remains a possibility that must be demonstrated through cost-effectiveness and budget-impact analyses.
In Europe, its regulatory development has already reached an important milestone. In July 2026, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the authorization of Ubeslo, obicetrapib 10 mg tablets, and Evlarco, the fixed-dose combination of obicetrapib and ezetimibe, for the treatment of adults with primary hypercholesterolemia or mixed dyslipidemia. As of September 2026, both recommendations remain subject to the formal decision of the European Commission.
Clinical trials have shown particularly substantial reductions in LDL cholesterol when obicetrapib is combined with ezetimibe. The combination has achieved reductions approaching 50% compared with placebo, while obicetrapib added to background lipid-lowering therapy has produced reductions of around 35%.
The decisive question, however, remains unanswered. Lowering LDL cholesterol is a validated therapeutic objective, but the true test of any new cardiovascular drug is whether that reduction translates into fewer heart attacks, strokes and cardiovascular deaths.
The Definitive Test: The history of cardiology is paved with molecules that shone brightly in the laboratory but failed when confronted with clinical reality. Improving a biomarker does not guarantee a reduction in cardiovascular events. That is precisely the lesson taught by the first generation of CETP inhibitors.
Torcetrapib, the first major member of this class, produced a spectacular rise in HDL cholesterol, but the ILLUMINATE trial was terminated prematurely in 2006 because treatment was associated with increased mortality and cardiovascular events. The problem was not attributed to CETP inhibition itself, but to off-target pharmacological effects of torcetrapib, including increases in blood pressure and aldosterone.
Dalcetrapib provided a different lesson. It increased HDL cholesterol but failed to reduce cardiovascular events in the dal-OUTCOMES trial.
Evacetrapib pushed lipid modification even further, producing a striking increase in HDL cholesterol and a reduction in LDL cholesterol of nearly 37%. Yet the ACCELERATE trial was stopped for lack of clinical benefit.
Only anacetrapib ultimately demonstrated a significant reduction in coronary events. In the REVEAL trial, published in The New England Journal of Medicine, it reduced major coronary events by approximately 9%. Merck nevertheless decided not to pursue commercial development. One factor underlying that decision was the drug’s extraordinarily prolonged persistence in the body and accumulation in adipose tissue, a consequence of its pharmacokinetic properties.
The experience made one point abundantly clear. Lipid-lowering efficacy must be accompanied by a sufficiently favorable pharmacological and safety profile.
Obicetrapib therefore enters a scientific landscape fully aware of the difficulties surrounding this therapeutic target. Its promise cannot be established simply by showing how much it raises HDL cholesterol or lowers LDL cholesterol. It must demonstrate that these changes translate into fewer clinically meaningful cardiovascular events.
That is the question PREVAIL was designed to answer. This phase 3, randomized, double-blind, placebo-controlled trial is specifically evaluating cardiovascular outcomes in patients with atherosclerotic cardiovascular disease who remain inadequately controlled despite maximally tolerated lipid-lowering therapy.
The study has enrolled 9,541 participants, and primary completion is currently estimated for November 2026.
BROADWAY has already provided an intriguing signal, but it must be interpreted cautiously. The trial observed a 21% relative reduction in an exploratory MACE endpoint, with a hazard ratio of 0.79 and a 95% confidence interval of 0.54 to 1.15. Because the study was neither designed nor powered to establish cardiovascular benefit, this finding does not demonstrate that obicetrapib reduces cardiovascular events.
A subsequent pooled analysis of BROADWAY and BROOKLYN showed a lower incidence of four-component MACE with obicetrapib, but the difference again did not reach statistical significance. The hazard ratio was 0.77, with a 95% confidence interval of 0.54 to 1.11.
The finding is therefore compatible with a potential clinical benefit, but remains insufficient to establish one.
Interest in obicetrapib has also extended to the brain. A prespecified analysis of Alzheimer’s disease biomarkers within BROADWAY included 1,727 participants, among them 367 APOE4 carriers. After one year of treatment, the increase in p-tau217 was smaller with obicetrapib than with placebo. In the overall population analyzed, the increase was 1.1% versus 4.8%.
The finding is scientifically intriguing, but it needs to be placed in its proper context. p-tau217 is a biomarker of Alzheimer’s disease pathology, not a clinical outcome. These results do not demonstrate that obicetrapib prevents Alzheimer’s disease or slows its progression. They are exploratory findings that raise an important hypothesis concerning the possible relationship between lipid metabolism, APOE4 and the biology of the aging brain.
And this may be the most fascinating aspect of the story. For years, CETP was a therapeutic target marked by successive disappointments. Now, a new CETP inhibitor is demonstrating a remarkable ability to modify the atherogenic lipid profile while generating preliminary signals that warrant investigation beyond the cardiovascular system.
But the story has not yet been written.
PREVAIL is the crucial test that remains. If it demonstrates that the reduction in LDL cholesterol and other atherogenic particles achieved with obicetrapib translates into fewer cardiovascular events, the molecule will have shown more than that a CETP inhibitor can work. It will have demonstrated something even more compelling: that a therapeutic target can survive its early failures when pharmacology learns from them and finds a more precise way to exploit it.
Medical science does not advance by forgetting its failures, but by understanding why they occurred. In the case of CETP, that scientific memory may be about to become a second chance.
Today’s research is tomorrow’s therapy